2. Antibody-drug Conjugate/ADC Related
  3. Antibody-Drug Conjugates (ADCs)
  4. Polatuzumab vedotin

Polatuzumab vedotin 

Cat. No.: HY-132253 Purity: 98.87%
COA

Molarity Calculator

Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL).

For research use only. We do not sell to patients.

Polatuzumab vedotin Chemical Structure

Polatuzumab vedotin Chemical Structure

CAS No. : 1313206-42-6

Size Price Stock Quantity
1 mg USD 881 In-stock
5 mg USD 2650 In-stock
10 mg USD 4240 In-stock
25 mg USD 8480 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Polatuzumab vedotin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL)[1].

In Vivo

Polatuzumab vedotin (0.3, 1, 3, 6, 12 mg/kg; i.v.; once) shows anti-tumor in a mouse tumour xenograft model of human diffuse large B‐cell lymphoma WSU‐DLCL2[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID mice (human diffuse large B-cell lymphoma WSU-DLCL2)[2]
Dosage: 0.3, 1, 3, 6, 12 mg/kg
Administration: I.v.; once
Result: Showed dose-dependent tumour growth inhibition.
Clinical Trial
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

[Polatuzumab vedotin]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Polatuzumab vedotin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Polatuzumab vedotin1313206-42-6Antibody-Drug Conjugates (ADCs)Antibody-Drug Conjugatesantibody-drugLarge B-cell lymphomasanti-tumorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Polatuzumab vedotin
Cat. No.:
HY-132253
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.